Why the study?
Does candesartan cilexetil or enalapril improve proteinuria, hypercholesterolemia, and renal histological changes in spontaneously hypercholesterolemic rats?
Does candesartan cilexetil or enalapril improve proteinuria, hypercholesterolemia, and renal histological changes in spontaneously hypercholesterolemic rats?
Candesartan cilexetil and enalapril provide renal protection in a rat model of hypercholesterolemia and focal glomerulosclerosis, suggesting a role for angiotensin II in this pathogenesis.
Should not inform clinical use in hypercholesterolemic nephropathy; leaves open angiotensin II role in rat glomerulosclerosis.
Spontaneously hypercholesterolemic (SHC) rats exhibit hypercholesterolemia, proteinuria and focal glomerulosclerosis with age, and they finally die as a result of renal failure. In this study, the renoprotective effects of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, and enalapril, an angiotensin I converting enzyme inhibitor, were examined in SHC rats. Candesartan cilexetil (0.1 and 1 mg /kg) and enalapril (10 mg/kg) were administered orally to 10-week-old SHC rats for a 6-week period. Candesartan cilexetil (1 mg/kg) and enalapril (10 mg/kg) significantly inhibited proteinuria and hypercholesterolemia to a similar extent. In untreated 16-week-old SHC rats, glomerulosclerosis, basophilic change, cast formation and interstitial mononuclear cell infiltration were observed. Candesartan cilexetil (1 mg/kg) inhibited all of these histological changes. Enalapril inhibited glomerulosclerosis and cast formation. These results show that candesartan cilexetil and enalapril have renal protective effects in SHC rats. Thus, angiotensin II might play an important role in renal pathogenesis in a model of focal glomerulosclerosis with hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Matsuo et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: